Ozempic NAION Warning: FDA Adds Rare Eye Risk to Every GLP-1 Drug Label
The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn of NAION, a rare cause of sudden vision loss. Here…
The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn of NAION, a rare cause of sudden vision loss. Here…
A CDSCO expert panel recommended a Phase I trial of Indian Immunologicals' live attenuated Zika vaccine, developed with Griffith University and funded by ICMR.
PMV Pharmaceuticals' rezatapopt produced a 48% response rate in platinum-resistant ovarian cancer with TP53 Y220C in the pivotal PYNNACLE trial, with an FDA filing planned…
Mayo Clinic data from ObesityWeek 2026 show GLP-1 users with weakened hearts saw greater one-year gains in heart structure and function than matched non-users, with…
Up to 15 people have died and more than 300 have sought care in Imphal after drinking spurious liquor in Manipur's Chandel district. What we…
The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn…
FDA accepts the oral infigratinib NDA for achondroplasia with Priority Review and a 4 February 2027 goal date. See the PROPEL 3 data and what happens next.
Epcoritamab plus R-CHOP met the primary PFS endpoint in the Phase 3 EPCORE DLBCL-2 trial, cutting progression risk 51%. What it means for DLBCL.
Lilly adds a target to its Gate Bioscience molecular gates collaboration, with total potential value above $870M. What is and is not disclosed.
CSL pays $355M upfront in a partnership with Alentis to co-develop lixudebart for rare kidney and liver diseases, worth up to about $1.6B.
FDA granted HeartBeam Breakthrough Device Designation for its 3D ECG system to help physicians assess suspected heart attacks, including at home.
FDA has cleared AIRS Medical’s SwiftSight Body Composition, AI software that measures fat, muscle and liver fat from an MRI scan of under five minutes.
Axogen closed its $200 million cash purchase of BioCircuit on 1 October, adding NerveTape, an FDA-cleared sutureless nerve repair device, to its portfolio.
Everest Medicines’ application to make Velsipity locally in China won priority review; production is anticipated in 2027 at about 50 million tablets a year.
Indian insurers are weighing a 10% co-pay on hospital claims, capped at Rs 5 lakh, from 1 January 2027 in exchange for lower premiums. What it means.
Six drones hit Kusum Healthcare's Sumy plant in Ukraine, killing an engineer; co-founder Sanjeev Gupta says it could stay shut for one to two years.